Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
05/16/2001 | EP1098659A2 Libraries of polyhydroxamates and their analogs |
05/16/2001 | EP1098655A2 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
05/16/2001 | EP1098650A1 Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof |
05/16/2001 | EP1098642A1 Methods for treating conditions modulated by lactosylceramide |
05/16/2001 | EP1098637A1 Transdermal patch and topical compositions comprising propylnorapomorphine |
05/16/2001 | EP1011647A4 Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith |
05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
05/16/2001 | EP0859766B1 Chiral methyl phenyl oxazolidinones |
05/16/2001 | EP0839136B1 BENZO[g]QUINOLINE DERIVATIVES |
05/16/2001 | CN1295612A Mutant herpes simplex viruses and uses thereoe |
05/16/2001 | CN1295563A 2-arylethyl-(piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists |
05/16/2001 | CN1295558A Novel local anesthetic compounds and uses |
05/16/2001 | CN1295479A Beta 2-adrenergic receptor agonist |
05/16/2001 | CN1295478A Novel galanic formulation of meloxicam for oral administration |
05/16/2001 | CN1295473A Use of dexmedetomidine for ICU sedation |
05/16/2001 | CN1295471A Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders |
05/16/2001 | CN1295470A Transdermal terapeutic system which contains D2 agonist and which is provided for treating parkinsonism, and method for production thereof |
05/16/2001 | CN1295464A Solid, quick dissolving cetirizine fomulation |
05/16/2001 | CN1295463A Fizzy formulation |
05/16/2001 | CN1295072A New polycyclic system compound as neurotransmitter release reinforcer in treatment of identification fault and derivatives thereof |
05/16/2001 | CN1295065A Phenyl heterocyclic compound used as epoxy enzyme -2 inhibitor |
05/16/2001 | CN1294928A Sobering-up tea and its making process |
05/16/2001 | CN1294918A Drug refraining medicine and its proportioning method |
05/16/2001 | CN1294913A Pharmaceutical use of compound |
05/16/2001 | CN1294911A Substituted nitrobenzene derivative for medicine and other use |
05/16/2001 | CN1065861C Phenyl substituted alkenocarboxylic guanidine, preparation method application as medicine or diagnostic agent and medicine containing it |
05/16/2001 | CN1065768C Methods of treatment of motor neuron cliseases using members of BDNF/NT-3/NGF family of molecule |
05/16/2001 | CN1065763C Dizziness-stopping analgesic |
05/15/2001 | US6232459 Synaptojanin isoform |
05/15/2001 | US6232449 Persephin and related growth factors |
05/15/2001 | US6232350 Administering triphenylethylene antiestrogens (tamoxifen and derivatives-neuroprotectants) to act as cell-nucleus receptor blockers |
05/15/2001 | US6232345 Cerebral function improving agents |
05/15/2001 | US6232329 Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles |
05/15/2001 | US6232321 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
05/15/2001 | US6232319 Substituted tetrahydropyridin derivatives, method of preparation and pharmaceutical compositions containing them |
05/15/2001 | US6232315 Method for treating inflammatory diseases by administering a thrombin inhibitor |
05/15/2001 | US6232314 Arylalkylpiperazine compounds as antioxidants |
05/15/2001 | US6232313 Pyridazino quinoline compounds |
05/15/2001 | US6232305 Substituted amino bicyclic-β-lactam penam and cepham derivatives as cysteine protease inhibitors |
05/15/2001 | US6232294 Glycosyl vitamin p and trehalose; nervous system, sleep, eating, psychological, and gastrointestinal disorders |
05/15/2001 | US6232286 Methods of stimulating mitogenesis in glial cells using glial mitogenic factors |
05/15/2001 | US6232118 Nucleic acid encoding a protein of defined amino acid sequence; recombinant cell culture production; diagnosis; probes; treatment of parkinson's disease and other nervous system disorders with reduced side effects; gene therapy |
05/15/2001 | US6232097 Nucleotide sequences coding enzymatic polypeptide; prevent bacterial infection; wound healing agents; for vaccine development |
05/15/2001 | US6232082 Vaccines |
05/15/2001 | US6232077 Genetic engineering and expression; cancer diagnosis |
05/15/2001 | US6231886 Methods of providing sustained treatment with opioids |
05/15/2001 | US6231833 Administering to the mammal for treating serotonin system related disorders an effective amount of 2,7-substituted octahydro-1h-pyrido(1,2-a)pyrazine derivative as ligands for serotonin receptor |
05/15/2001 | US6231594 Method of controlling body temperature while reducing shivering |
05/15/2001 | CA2310845C Treatment of neuromuscular disorders and conditions with different botulinum serotype |
05/15/2001 | CA2180011C Botulinum toxins for treating sweating |
05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
05/10/2001 | WO2001032910A2 27 human secreted proteins |
05/10/2001 | WO2001032888A2 Human transferase molecules |
05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
05/10/2001 | WO2001032709A2 Polypeptides with non-natural primary signalling motifs |
05/10/2001 | WO2001032704A1 Choline transporter like (ctl) membrane proteins involved in choline transport |
05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
05/10/2001 | WO2001032687A1 10 human secreted proteins |
05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
05/10/2001 | WO2001032676A1 25 human secreted proteins |
05/10/2001 | WO2001032675A1 32 human secreted proteins |
05/10/2001 | WO2001032674A1 26 human secreted proteins |
05/10/2001 | WO2001032663A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
05/10/2001 | WO2001032659A1 Isoquinoline and quinazoline derivatives for the treatment of cns disorders |
05/10/2001 | WO2001032656A1 Polymorphic form of a tachykinin receptor antagonist |
05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
05/10/2001 | WO2001032649A1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof |
05/10/2001 | WO2001032647A2 Benz`f!indoles for use in the treatment of 5ht receptor related disorders |
05/10/2001 | WO2001032646A2 Sulfonamide derivatives |
05/10/2001 | WO2001032640A1 1-cyclic amino-alkylcyclohexane compounds, pharmaceutical compositions thereof, and their use as anticonvulsants |
05/10/2001 | WO2001032639A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
05/10/2001 | WO2001032634A1 2-cyclohexyl benzimidazole nmda/nr2b antagonists |
05/10/2001 | WO2001032629A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
05/10/2001 | WO2001032626A1 Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
05/10/2001 | WO2001032625A1 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
05/10/2001 | WO2001032624A1 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
05/10/2001 | WO2001032622A1 Positive modulators of nicotinic receptor agonists |
05/10/2001 | WO2001032620A1 Positive modulators of nicotinic receptor agonists |
05/10/2001 | WO2001032619A1 Positive modulators of nicotinic receptor agonists |
05/10/2001 | WO2001032618A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
05/10/2001 | WO2001032615A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
05/10/2001 | WO2001032606A1 Compounds having mif antagonist activity |
05/10/2001 | WO2001032602A1 Diaryl-enynes |
05/10/2001 | WO2001032601A1 Polymorphic forms of sertraline hydrochloride |
05/10/2001 | WO2001032595A1 Method for producing compounds of the valproinic acid |
05/10/2001 | WO2001032264A1 Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
05/10/2001 | WO2001032216A2 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
05/10/2001 | WO2001032196A1 Secretin fragments for treating autism |
05/10/2001 | WO2001032183A2 Pharmaceutical compositions comprising oxcarbazepine |
05/10/2001 | WO2001032179A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
05/10/2001 | WO2001032178A1 Use of 3,4-substituted piperidines |
05/10/2001 | WO2001032177A1 2-aza-bicyclo[2.2.2]octane nmda/nr2b antagonists |
05/10/2001 | WO2001032176A1 Beta-carboline derivatives for use as analgesics |
05/10/2001 | WO2001032174A1 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists |